Bristol-Myers Squibb announced that its Phase II clinical trial of BMS-986165 for moderate to severe plaque psoriasis hit its efficacy endpoints.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,